Abstract:Background Regulatory T (Treg) cells are a key component in maintaining the suppressive tumor microenvironment and immune suppression in different types of cancers. A precise understanding of the molecular mechanisms used by Treg cells for immune suppression is critical for the development of effective strategies for cancer immunotherapy. Methods Senescence development and tolerogenic functions of dendritic cells (DCs) induced by breast cancer tumor-derived γδ Treg cells were fully characterized using real-time PCR, flow cytometry, western blot, and functional assays. Loss-of-function strategies with pharmacological inhibitor and/or neutralizing antibody were used to identify the potential molecule(s) and pathway(s) involved in DC senescence and dysfunction induced by Treg cells. Impaired tumor antigen HER2-specific recognition and immune response of senescent DCs induced by γδ Treg cells were explored in vitro and in vivo in humanized mouse models. In addition, the DC-based HER2 tumor vaccine immunotherapy in breast cancer models was performed to explore the enhanced antitumor immunity via prevention of DC senescence through blockages of STAT3 and programmed death-ligand 1 (PD-L1) signaling. Results We showed that tumor-derived γδ Treg cells promote the development of senescence in DCs with tolerogenic functions in breast cancer. Senescent DCs induced by γδ Treg cells suppress Th1 and Th17 cell differentiation but promote the development of Treg cells. In addition, we demonstrated that PD-L1 and STAT3 signaling pathways are critical and involved in senescence induction in DCs mediated by tumor-derived γδ Treg cells. Importantly, our complementary in vivo studies further demonstrated that blockages of PD-L1 and/or STAT3 signaling can prevent γδ Treg-induced senescence and reverse tolerogenic functions in DCs, resulting in enhanced HER2 tumor-specific immune responses and immunotherapy efficacy in human breast cancer models. Conclusions These studies not only dissect the suppressive mechanism mediated by tumor-derived γδ Treg cells on DCs in the tumor microenvironment but also provide novel strategies to prevent senescence and dysfunction in DCs and enhance antitumor efficacy mediated by tumor-specific T cells for cancer immunotherapy.

An association between elevated telomerase reverse transcriptase expression and the immune tolerance disruption of dendritic cells

Disturbance of Differentiation and Maturation of Dendritic Cells and Tumor Escape

Discriminating Association of a Common Telomerase Reverse Transcriptase Promoter Polymorphism with Telomere Parameters in Non-Small Cell Lung Cancer with or Without Epidermal Growth Factor Receptor Mutation.

TERT activates endogenous retroviruses to promote an immunosuppressive tumour microenvironment

Tolerogenic dendritic cells: the ins and outs of outcome.

Integrin CD11b Negatively Regulates TLR9-triggered Dendritic Cell Cross-Priming by Upregulating Microrna-146A.

Abstract 973: Telomere Stress Potentiates Host STING-dependent Anti-Tumor Immunity

Lymphatic-localized Treg-mregDC crosstalk limits antigen trafficking and restrains anti-tumor immunity

Deciphering the impact of TERT/telomerase on immunosenescence and T cell revitalization

Impaired function of dendritic cells within the tumor microenvironment

Blocking senescence and tolerogenic function of dendritic cells induced by γδ Treg cells enhances tumor-specific immunity for cancer immunotherapy

Abstract 5036: Tumor-induced Activation of the Wnt/β-catenin/TCF4 Pathway in Dendritic Cells Promotes Immune Tolerance

Thyroid carcinoma-featured telomerase activation and telomere maintenance: Biology and translational/clinical significance

Exploring dendritic cell subtypes in cancer immunotherapy: unraveling the role of mature regulatory dendritic cells

Potential Role of Plasmacytoid Dendritic Cells for FOXP3+ Regulatory T Cell Development in Human Colorectal Cancer and Tumor Draining Lymph Node.

Mature dendritic cells enriched in immunoregulatory molecules (mregDCs): A novel population in the tumour microenvironment and immunotherapy target

Feedback regulation of telomerase reverse transcriptase: new insight into the evolving field of telomerase in cancer

Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players

An inducible CRISPR/Cas9 screen identifies DTX2 as a transcriptional regulator of human telomerase

Tumor microenvironment-related dendritic cell deficiency: a target to enhance tumor immunotherapy

Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical Implications